Latest article
Are Buyers Undervaluing Tandem Diabetes Care, Inc. (NASDAQ:TNDM) By 43%?
Today we're doing a simple run of a valuation methodology that will estimate the attractiveness of Tandem Diabetes Care, Inc....
Ropes & Grey Provention Bio Securities Case Diabetes Drug teplizumab
Yenis V. Argueta Guevara of Ropes & Gray has filed for drug developer Protection Bio and its top executives in...